{'52WeekChange': 0.891253,
 'SandP52WeekChange': 0.0644362,
 'address1': '3 More London Riverside',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.99,
 'askSize': 1800,
 'averageDailyVolume10Day': 12620725,
 'averageVolume': 1645419,
 'averageVolume10days': 12620725,
 'beta': -0.795348,
 'beta3Year': None,
 'bid': 7.57,
 'bidSize': 1200,
 'bookValue': 6.56,
 'category': None,
 'circulatingSupply': None,
 'city': 'London',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8.39,
 'dayLow': 7.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 105453360,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.6875715,
 'fiftyTwoWeekHigh': 15.71,
 'fiftyTwoWeekLow': 2.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 13114049,
 'forwardEps': -4.08,
 'forwardPE': -1.9607843,
 'fromCurrency': None,
 'fullTimeEmployees': 33,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.49798,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/veronapharma.com',
 'longBusinessSummary': 'Verona Pharma plc, a clinical stage biopharmaceutical '
                        'company, focuses on develops and commercializes '
                        'therapies for the treatment of respiratory diseases '
                        'with unmet medical needs. Its product candidate, '
                        'ensifentrine (RPL554), is an inhaled, dual inhibitor '
                        'of the enzymes phosphodiesterase 3 and 4 that acts as '
                        'both a bronchodilator and an anti-inflammatory agent '
                        'in a single compound. The formulations of '
                        'ensifentrine are under development for the treatment '
                        'chronic obstructive pulmonary disease (COPD): '
                        'nebulized ensifentrine is in Phase 2b clinical '
                        'development for the maintenance treatment of COPD; '
                        'and a dry powder inhaler and a pressurized '
                        'metered-dose inhaler. The company also focuses on '
                        'developing ensifentrine for the treatment of cystic '
                        'fibrosis and asthma. Verona Pharma plc was founded in '
                        '2005 and is headquartered in London, the United '
                        'Kingdom.',
 'longName': 'Verona Pharma plc',
 'market': 'us_market',
 'marketCap': 105920000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_25217246',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 8.33,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 20 3283 4200',
 'previousClose': 8.45,
 'priceHint': 2,
 'priceToBook': 1.2195122,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8.39,
 'regularMarketDayLow': 7.51,
 'regularMarketOpen': 8.33,
 'regularMarketPreviousClose': 8.45,
 'regularMarketPrice': 8.33,
 'regularMarketVolume': 432092,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 13317000,
 'sharesPercentSharesOut': 0.0011999999,
 'sharesShort': 16155,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7190,
 'shortName': 'Verona Pharma plc',
 'shortPercentOfFloat': None,
 'shortRatio': 0.41,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'VRNA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.336,
 'twoHundredDayAverage': 5.1876545,
 'volume': 432092,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.veronapharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'SE1 2RE'}